newsfilter
← Latest News
Business Wire·

Acadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference

ACAD
  • Acadia Pharmaceuticals Inc. will present two data sets on Alzheimer's disease psychosis (ADP) & remlifanserin at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston from November 16-19, 2026.
  • An oral presentation (OC7) scheduled for November 17, 2026, will detail efficacy & safety findings from the Phase 2 portion of the RADIANT clinical trial program.
  • A poster presentation (P303) scheduled for November 18, 2026, will examine biomarker heterogeneity among ADP patients who are negative for amyloid proteinopathy & p-Tau217.
  • The RADIANT program is a global, multi-center, randomized, double-blind, placebo-controlled Phase 2 & 3 trial evaluating remlifanserin for hallucinations & delusions associated with ADP.
  • The Phase 2 portion assessed remlifanserin at 60 mg & 30 mg once daily doses compared to placebo.
  • Participants completing RADIANT studies may enroll in a long-term open-label extension (OLE) study.
  • Approximately 30% of the over 7 million U.S. residents aged 65+ with Alzheimer's disease experience psychosis, which is linked to higher nursing home placement rates & increased mortality.
  • No FDA-approved drug currently exists for the treatment of Alzheimer's disease psychosis.
  • Remlifanserin is a novel, highly selective 5-HT2A receptor inverse agonist being developed for ADP & Lewy body dementia psychosis.
  • Acadia Pharmaceuticals holds the first & only FDA-approved treatments for Parkinson's disease psychosis & Rett syndrome.